Outpatient cervical ripening using a sustained-release prostaglandin E2 vaginal insert.
This clinical trial was undertaken to determine whether a sustained-release prostaglandin E2 vaginal insert could be used for outpatient cervical ripening. A total of 111 patients, with primarily pregnancy-induced hypertension or postdatism, were administered the insert in a simulated outpatient setting. The high rates of regular contractions (23.4%) and of removal of the insert before < 12 hours (27.9%) make its use undesirable outside a hospital.
Tassone
S A
SA
Department of Obstetrics and Gynecology, University of Oklahoma, Health Sciences Center, Oklahoma City.
Pearman
C R
CR
Rayburn
W F
WF
D000293:Adolescent; D000328:Adult; D020070:Cervical Ripening / Q000187:drug effects*; D003692:Delayed-Action Preparations; D015232:Dinoprostone / Q000008:administration & dosage* / Q000494:pharmacology*; D005260:Female; D006801:Humans; D010045:Outpatients; D010349:Patient Compliance; D011247:Pregnancy; D014590:Uterine Contraction / Q000187:drug effects; D014621:Vagina
D003692:Delayed-Action Preparations; D015232:Dinoprostone